Germany company Adrenomed raises €24 million to push Adrecizumab’s clinical trial

German privately financed vascular integrity company Adrenomed has closed a €24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.

According to the press release Adrenomed issued on Tuesday, the new funds will be invested in the clinical development program of lead product candidate Adrecizumab, which is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM).

Adrenomed’s lead candidate Adrecizumab is a monoclonal antibody targeting Adrenomedullin, with the most important target indications beign sepsis and septic shock.

Dr. Andreas Bergmann, CSO of Adrenomed said that there is a very high unmet medical need to rescue vascular integrity in septic patients in intensive care. “Septic shock is a life-threatening condition affecting millions of people worldwide with a remaining high mortality rate of approximately 30-50%,” he pointed out.

Dr. Gerald Moeller, CEO of Adrenomed, said: “We are excited about Wellington Partners and HBM Healthcare Investments joining as new and highly experienced investors. This financing is an important validation of our unique therapeutic approach and will help us target the global market opportunity for Adrecizumab in sepsis.”

Dr. Rainer Strohmenger, Managing Partner at Wellington Partners believes that that Adrecizumab may be the first approach to actually rescue vascular integrity in patients with early septic shock. Strohmenger also said that Adrecizumab may also be effective in addressing unmet needs in further life-threating and, so far, difficult to treat diseases associated with SIRS, endothelial barrier dysfunction, edema and tissue congestion.

Dr. Priyanka Belawat, Investment Advisor at HBM Partners commented that with these funds, Adrenomed can be able to transform this concept into a breakthrough therapy with the potential to improve and save lives.